Pseudomonas aeruginosa is a leading opportunistic pathogen in healthcare settings, causing a range of infections including pneumonia, bloodstream infections, UTIs, and wound or burn-site infections especially in immunocompromised or critically ill patients.
Antimicrobial resistance rates of the pathogen show marked regional variation, with Europe reporting higher levels compared to other parts of the world.
P. aeruginosa can spreads through contact with contaminated surfaces or equipment. It can also spread through exposure in the soil or water, person-to-person contact (e.g. contaminated hands).
P. aeruginosa can cause infections in the blood, lungs (pneumonia), urinary tract, or other parts of the body after surgery.
P. aeruginosa ranks among the top contributors to AMR-related mortality, accounting for hundreds of thousands of deaths.
Monoclonal antibody (1)
Phase II (1)
Paediatric + Adults + Older Adults (1)
Source:
Molly Kukua Abban, Eunice Ampadubea Ayerakwa, Lydia Mosi, Abiola Isawumi, The burden of hospital acquired infections and antimicrobial resistance, Heliyon, Volume 9, Issue 10, 2023, e20561, ISSN 2405-8440.
Elfadadny Ahmed, Ragab Rokaia F., AlHarbi Maha, Badshah Farhad, Ibรกรฑez-Arancibia Eliana, Farag Ahmed, Hendawy Amin Omar, De los Rรญos-Escalante Patricio R., Aboubakr Mohamed, Zakai Shadi A., Nageeb Wedad M. Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies. Frontiers in Microbiology. Volume 15 โ 2024. 2024. DOI=10.3389/fmicb.2024.1374466. ISSN=1664-302X
CDC. https://www.cdc.gov/pseudomonas-aeruginosa/about/index.html
